Le Lézard
Classified in: Health
Subject: SVY

The global cholera vaccines market size is expected to reach USD 117.1 million by 2025



LONDON, Sept. 25, 2018 /PRNewswire/ -- Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025



Download the full report: https://www.reportbuyer.com/product/5568375



The global cholera vaccines market size is expected to reach USD 117.1 million by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 8.2% during the forecast period. Increase in number of initiatives and rising awareness about cholera are major factors contributing toward market growth.

Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure.In February 2013, the Government of Haiti launched a 10-year National Cholera Elimination Plan.

The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.

Furthermore, various research projects and studies, such as epidemiological and anthropological studies, are being conducted in Africa.Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks.

The Cholera Platform is working with the Global Task Force for Cholera Control (GTFCC) WASH working group. This association aims to develop a method for conducting case studies to control and prevent the disease.

Further key findings from the report suggest:
? The global market size was estimated at USD 63.1 million in 2017 and is expected to register a CAGR of 8.2% from 2017 to 2025
? By product, Dukoral vaccine dominated the market in 2017. The dominance can be attributed to the positive outcomes of this vaccine in preventing the disease since 2004. Dukoral is considered to be safe and stable
? The Vaxchora segment is expected to exhibit a lucrative CAGR over the forecast period owing to benefits associated with the vaccine, such as single dose immunization and reduced adverse effects
? Asia Pacific held the largest share in 2017 due to factors such as increasing incidence and growing initiatives for raising awareness about the disease and vaccination
? North America is anticipated to witness lucrative growth over the next decade due to a recent product launch and increasing number of travelers
? Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc.

Download the full report: https://www.reportbuyer.com/product/5568375

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 11:30
FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world's first 85cm wide bore computed tomography (CT)...

at 10:00
During its Users Meeting at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Varian shared details of its development work on an artificial intelligence (AI)-driven multimodality adaptive radiotherapy treatment suite that is...

at 09:30
Varian today announced the Bravostm afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic experience by...

at 09:00
DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that data from systemic lupus erythematosus (SLE) and multiple sclerosis (MS) studies will be...

at 09:00
Royal Philips , a global leader in health technology, is showcasing its new suite of radiation oncology systems and software at the American Society for Radiation Oncology's (ASTRO) 60th Annual Meeting and Exhibition in San Antonio, Texas. Seamlessly...

at 08:59
BioArctic AB (publ) announced today that the European Patent Office (EPO) has issued a decision to grant the company's patent application in Europe, EP09738534.8, for its Parkinson's disease concept patent. The decision states that the European...




News published on 25 september 2018 at 21:44 and distributed by: